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After the publication of this work [1], it was brought
to our attention that two points needed to be explained
further.
The first point was regarding the GAPDH immunoblot
in Fig. 6c. We had performed this experiment in tripli-
cate. The images used for phospho- and total MET in
Fig. 6c were derived from the third replicate of the
experiment, but accidentally we used the GAPDH
from the second replicate of the experiment.
The revised Fig. 6c can be seen at the end of this Erratum
with the corresponding and correct GAPDH image.
The interpretation of the results and findings of our
investigations remain unchanged. As such, the results
section that describes Fig. 6c remains the same. Also,
correct images were used for quantification of the bands,
and hence the quantitation figure (Fig. 6d) and associ-
ated text also do not change. Our findings remain valid
and our inadvertent error did not affect our results,
discussion, or the conclusions from this work, as the
text refers to the correct values. We sincerely regret
our error and apologize for any confusion this may
have caused.
The second point was regarding similarity in the
GAPDH and GSK-3β immunoblot (last 2 rows) in Fig.
7c. To generate this figure, protein lysates from each ex-
periment were run on two different gels and transferred.
The membranes from both gels were cut based on* Correspondence: vgandhi@mdanderson.org
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the immunoblot containing proteins above ~80 kDa
and a second piece containing proteins below ~80
kDa. The pieces of membranes above ~80 kDa were
probed for Total and phospho-Met (quantitation of
these blots were used in Fig. 6). Lower portions were
used for Fig. 7c. One was used for phospho- and
total-ERK and corresponding GAPDH. The other was
used for phospho and total AKT (around 60 kDa)
and phospho and total GSK-3β (around 40 kDa),
along with GAPDH (around 37 kDa).
The lower 5 rows of the immunoblot were all from
the same membrane and were probed as below. The
membrane was first probed with a rabbit anti-phospho-
AKT (S473) antibody followed by the secondary, which
was a green fluorescent anti-rabbit antibody. Next, we
probed with a mouse anti-total-AKT antibody followed
by the secondary, which was a red fluorescent anti-
mouse antibody. Next, we probed the blot with a rabbit
anti-phospho-GSK-3β (S9) antibody followed by the
secondary, which was a green fluorescent anti-rabbit
antibody. Next, we probed with a mouse anti-total-
GSK-3β antibody followed by the secondary, which was
a red fluorescent anti-mouse antibody. Lastly, we
probed with a mouse GAPDH antibody followed by the
secondary red fluorescent anti-mouse antibody. We use
a fluorescence based imaging system, LiCor Odyssey, to
analyze immunoblots. With this system, our secondary
antibodies against primary antibodies derived from dif-
ferent species are tagged with different fluorescence
colors. The Odyssey software allows us to image each
fluorescent channel separately as well and convert color
image to grey scale image for publication. Because all 5
rows were from the same gel, and GSK3beta is fairlyle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 6 U266 cells were serum starved and treated with the indicated concentrations of amuvatinib or DMSO and stimulated with 50 ng/ml HGF
for 15 min. Cell lysates were subjected to immunoblot analysis. After transfer, the membrane was cut around 80 kDa and top portion was used
for this figure while lower (<80 kDa was used for GAPDH as well as quantitation of proteins in Fig. 7d and e). To assess MET (Y1349) phosphorylation
and total MET, the upper portion of the membrane was first probed with a rabbit anti-phospho-MET (Y1349) antibody followed by the
secondary, which was a green fluorescent anti-rabbit antibody. Next, we probed with a mouse anti-total-MET antibody followed by the
secondary, which was a red fluorescent anti-mouse antibody. The last antibody, the bottom portion of the membrane was probed with,
was a mouse GAPDH antibody followed by the secondary red fluorescent anti-mouse antibody. We used a fluorescence based imaging
system, LiCor Odyssey. The Odyssey software was used to convert color image to grey scale image for publication
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proteins appear similar. However, they are separate im-
munogenic reacted proteins as described above. This
experiment was done in biological triplicate and quanti-
tated using Odyssey Imaging software. The quantitated
values were graphed in Fig. 7d, 7e, and 7f of the same
published paper.
Because there were no errors in this figure, the published
Fig. 7c is correct.
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